Özdemir, Ö.Zengel, B.Yildiz, Y.Uluç, B.O.Cabuk, D.Ozden, E.Alacacioglu, A.2025-05-102025-05-1020220959-497310.1097/CAD.00000000000013102-s2.0-85134433317https://doi.org/10.1097/CAD.0000000000001310https://hdl.handle.net/20.500.14720/2999In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches. © 2022 Lippincott Williams and Wilkins. All rights reserved.eninfo:eu-repo/semantics/closedAccessBreast CancerNeoadjuvant ChemotherapyPathological ResponsePertuzumabArticle337Q3Q366367035703239